Clinical Chemistry News
-
Optimizing Monoclonal Antibody Production: Temperature And Osmolality’s Impact, Upcoming Webinar Hosted By Xtalks
In this free webinar sponsored by Advanced Instruments, gain insights into advances in monoclonal antibody production technology and manufacturing strategies. Attendees will learn why temperature and osmolality in cell culture are critical parameters affecting cell growth, viability and the concentration of HCPs in the supernatant. The featured speaker will discuss how temperature and osmolality ...
-
Medical Equipment Pump Solutions
Medical Equipment Pump Solutions Industry Overview IVD, which stands for in vitro diagnostics, refers to products that conduct testing on samples taken from the human body (such as blood, body fluids, and tissues) outside of the body in order to obtain clinical diagnostic information. The IVD industry is subdivided into various sectors including immunodiagnostics, clinical chemistry, molecular ...
-
Alfa Chemistry-A New Supplier of Vaccine Excipients, Nucleic Acid Delivery Excipients and SARS-CoV-2 Detection Raw Materials
Alfa Chemistry, known as a chemical supplier for various high-quality chemicals and materials for both academia and the industry, has recently extended its offering scope to vaccine related products, including but not limited to: vaccine excipients, nucleic acid delivery excipients, cell culture media and pharmaceutical packaging. “Always bearing in mind that what customers truly need is the top ...
-
Regor announces China NMPA approval of the IND for RGT-264 phosphate tablet, a potent and selective HPK1 inhibitor
Regor Therapeutics, a clinical-stage biotech company, announced today the Investigational New Drug (IND) Application for RGT-264 phosphate tablet, a small molecular selective hematopoietic progenitor kinase (HPK1) inhibitor has been approved by the National Medical Products Administration (NMPA) of China. RGT-264 phosphate tablet is a highly potent and selective HPK1 inhibitor. HPK1 kinase ...
-
Join us at AACC 2022
As a leading company for AI-Driven IVD equipments, Reetoo will be attending AACC (American Association for Clinical Chemistry), which will take place at the McCormick Place Convention Center in Chicago from July 26 to 28. We will bring our latest products to the exhibition as below, and look forward to meeting you at our booth #4060. RT-F600: Automatic Vaginal Secretion Analyzer ...
-
Saladax Biomedical, Inc. Acquires Intellectual Property Portfolio for Antipsychotic Drug Tests
Saladax Biomedical, Inc. (Saladax) is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio includes 17 patent families and has resulted in 33 U.S. patents and 296 patents in ex-U.S. countries. This IP, along with the current Saladax IP, covers the major antipsychotic drugs that are ...
-
Immundiagnostik`s Colorectal Cancer Screening Portfolio
Regular participation in colorectal cancer (CRC) screening programmes can reduce the number of colorectal cancer cases as well as mortality rates (Brenner et al., 2014; Zorzi et al., 2015)*. Quantitative Fecal Immunochemical Tests (FIT) are recommended for colorectal cancer population screenings. An advantage of quantitative tests is the ability to vary cut-off values, which allows an adaption to ...
-
Amerigo Scientific Introduces the Launch of Polystreptavidin 350
Amerigo Scientific, a distribution company focused on providing critical products and services to the biomedical and life science research communities, now introduces Polystreptavidin 350 for applications in lateral flow, ELISA or CLIA. Diagnosis is a key enabler of universal health coverage and the first line of defense against the spread of many diseases. From rapid treatment and combating ...
-
Saladax Biomedical, Inc. Announces Global Distribution Agreement With Beckman Coulter, Inc. for Antipsychotic Drug Tests
Saladax Biomedical, Inc. (Saladax) is pleased to announce the signing of a global distribution agreement with Beckman Coulter, Inc. to distribute the MyCare™ Psychiatry Laboratory Assays. The MyCare™ Psychiatry Laboratory Assays measure drug levels of the antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as such as Schizophrenia and Bipolar ...
-
Beckman Coulter Introduces Antipsychotic Drug Testing to Address Unmet Clinical Need for More Than 69 Million People Living with Serious Mental Conditions
Beckman Coulter, a global clinical diagnostics leader, announces it will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide. In a new agreement with Saladax Biomedical, Inc., Beckman Coulter will distribute the tests designed to measure blood levels of antipsychotic drugs ...
-
World Health Organization Panel Strongly Recommends The Use Of Baricitinib To Treat Hospitalised Patients With COVID-19
On Thursday, a panel of WHO experts strongly recommended the janus kinase (JAK) inhibitor baricitinib, a drug owned by Eli Lilly, for patients with severe or critical COVID-19 in combination with corticosteroids. BenevolentAI first identified baricitinib as a COVID-19 treatment candidate in January 2020 using its artificial intelligence (AI) platform. BenevolentAI was able to rapidly pinpoint ...
By Benevolent
-
BenevolentAI Announces 3-Year Collaboration Expansion With AstraZeneca Focused On Systemic Lupus Erythematosus And Heart Failure
Two novel targets identified through the existing collaboration have already been added to AstraZeneca’s portfolio London, 13 January 2021, BenevolentAI, a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca, doubling the number of disease areas being explored through the partnership. The three-year expansion includes ...
By Benevolent
-
Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor`s First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology
Regor Therapeutics, a clinical-stage biotech company, announced today authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans for RGT-419B. RGT-419B is a new generation CDK2/4/6, small molecule inhibitor with an optimized kinase activity spectrum. It is expected to improve the safety of and combat the resistance to currently ...
-
Quidel Corporation Signs Definitive Agreement to Acquire Ortho Clinical Diagnostics
Quidel Corporation (NASDAQ: QDEL) (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho”) today announced that they have entered into a definitive agreement in which Quidel will acquire Ortho, one of the world’s largest in vitro diagnostics companies, for $24.68 per share of common stock using a combination of cash and newly issued shares in ...
-
Regor and Lilly Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders
Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders. Under the terms of the agreement, Lilly will have a license to select Regor intellectual property with an option to extend the license. Lilly will be responsible for clinical ...
-
Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society
Data from IND-enabling studies show accurate delivery, targeted biodistribution, favorable safety profile, durable suppression of seizures and reduction in disease pathology A first-in-human Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy has been initiated and will begin recruiting soon Neurona Therapeutics, a clinical-stage biotherapeutics ...
-
Clip Health (formerly Luminostics) Announces Company Rebranding, Immediate Product Pipeline
Clip Health™, a fast-growing healthtech company and diagnostics innovator, today announced its DBA name change and company rebrand from its corporate name Luminostics, Inc. “Clip Health, as a name, aligns with our products’ central value of delivering speedy, easy-to-obtain access to your health data, thereby trimming inefficiencies in healthcare delivery”, said ...
By Clip Health
-
Clip Health (formerly Luminostics) Announces Company Rebranding, Immediate Product Pipeline
Clip Health™, a fast-growing healthtech company and diagnostics innovator, today announced its DBA name change and company rebrand from its corporate name Luminostics, Inc. “Clip Health, as a name, aligns with our products’ central value of delivering speedy, easy-to-obtain access to your health data, thereby trimming inefficiencies in healthcare delivery”, said ...
By Clip Health
-
Cytovale Begins Enrollment in FDA 510(k) Clinical Validation Study of IntelliSep Rapid Sepsis Test
Cytovale, a medical diagnostics company focused on providing a faster, more insightful way to diagnose fast-moving and immune-mediated diseases, today announced the first enrollment in a clinical trial of the Cytovale system and IntelliSep test to aid in the rapid assessment of potential for sepsis in the emergency department (ED). The trial, A Clinical Validation Solving the Question of ...
-
Peer-Reviewed Journal Publishes Analytical Validation Results for the PrecivityAD Blood Test, Which Can Help Clinicians Detect Alzheimer’s Disease
C2N Diagnostics, which offers the PrecivityAD™ blood test that can help detect if certain markers for Alzheimer’s disease are in the brain, now has its analytical validation results available for review. The study appears in Clinica Chimica Acta, the official peer-reviewed journal of the International Federation of Clinical Chemistry and Laboratory Medicine. The article is titled ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you